UCB Published P-III Studies (MycarinG) & (RAISE) of Rozanolixizumab and Zilucoplan for Generalized Myasthenia Gravis in The Lancet Neurology Journal
Shots:
- The P-III study (MycarinG) evaluating rozanolixizumab in adult patients with AChR-Ab+ or MuSK-Ab+ gMG & the P-III study (RAISE) of zilucoplan for AChR-Ab+ gMG
- In (MycarinG) study, improvements in MG-specific outcomes & reductions in MG-ADL score to day 43 were greater in the rozanolixizumab (7 & 10mg/kg) group over PBO; improvement in MG-ADL in MuSK-Ab+ & AChR-Ab+ subgroup (–7.28 & –4.16 vs 2.28) & ( –3.03 & –3.36 vs –1.10)
- In (RAISE) study, rapid efficacy & clinical improvements in patient & clinician-reported EPs, incl. MG-ADL, QMG, MGC & MGQoL15, ≥3 & ≥5-point reduction in MG-ADL & QMG score without rescue therapy (73% vs 46%) & (58% vs 33%) at 12wk. Both therapies were well tolerated. Regulatory applications for both therapies have been filed in Japan & responses are expected in H2’23
Ref: UCB | Image: UCB
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
